Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

详细信息    查看全文

• 作者：Elvira Valera ; Brian Spencer ; Eliezer Masliah
• 关键词：Immunotherapy ; Vaccines ; Antibodies ; Amyloid ; β ; α ; synuclein ; Tau
• 刊名：Neurotherapeutics
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：13
• 期：1
• 页码：179-189
• 全文大小：613 KB
• 参考文献：1.Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054-1061.PubMed CrossRef
  2.Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-1995.PubMed CrossRef
  3.Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010;19:R12-R20.PubMedCentral PubMed CrossRef
  4.Goedert M, Jakes R, Anthony Crowther R, Grazia Spillantini M. Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy as alpha-synucleinopathies. Methods Mol Med 2001;62:33-59.PubMed
  5.Spillantini MG. Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 1999;5:157-162.PubMed CrossRef
  6.Goedert M, Ghetti B, Spillantini MG. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006254.PubMedCentral PubMed CrossRef
  7.Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. Curr Alzheimer Res 2011;8:273-294.PubMedCentral PubMed CrossRef
  8.Winslow AR, Moussaud S, Zhu L, et al. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain 2014;137:1958-1970.PubMedCentral PubMed CrossRef
  9.Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 2009;117:125-136.PubMed CrossRef
  10.McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 2000;275:8812-8816.PubMed CrossRef
  11.Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477:107-110.PubMedCentral PubMed CrossRef
  12.Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 2012;33:431, e27-e38.PubMed
  13.Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002;322:1089-1102.PubMed CrossRef
  14.Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004;279:46363-46366.PubMed CrossRef
  15.Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 2003;4:21-36.PubMed CrossRef
  16.Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 2012;26:1946-1959.PubMedCentral PubMed CrossRef
  17.Lasagna-Reeves CA, Sengupta U, Castillo-Carranza D, et al. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun 2014;2:56.PubMedCentral PubMed CrossRef
  18.Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013;14:38-48.PubMedCentral PubMed CrossRef
  19.Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011;108:4194-4199.PubMedCentral PubMed CrossRef
  20.Umeda T, Tomiyama T, Sakama N, et al. Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 2011;89:1031-1042.PubMed CrossRef
  21.Meraz-Ríos MA, Lira-De León KI, Campos-Peña V, De Anda-Hernández MA, Mena-López R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 2010;112:1353-1367.PubMed CrossRef
  22.Domert J, Rao SB, Agholme L, et al. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis 2014;65:82-92.PubMed CrossRef
  23.Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010;11:155-159.PubMedCentral PubMed
  24.Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012;287:19440-19451.PubMedCentral PubMed CrossRef
  25.Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010;6:702-706.PubMed CrossRef
  26.Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010-13015.PubMedCentral PubMed CrossRef
  27.Stancu IC, Vasconcelos B, Ris L, et al. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathol 2015;129:875-894.PubMedCentral PubMed CrossRef
  28.Morales R, Callegari K, Soto C. Prion-like features of misfolded Abeta and tau aggregates. Virus Res 2015;207:106-112.PubMed CrossRef
  29.Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosc. 2010;30:7281-7289.CrossRef
  30.Masliah E, Rockenstein E, Veinbergs I, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:12245-12250.PubMedCentral PubMed CrossRef
  31.Do TD, Economou NJ, Chamas A, Buratto SK, Shea JE, Bowers MT. Interactions between amyloid-beta and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys Chem B 2014;118:11220-11230.PubMedCentral PubMed CrossRef
  32.Roy B, Jackson GR. Interactions between Tau and alpha-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet 2014;23:3008-3023.PubMedCentral PubMed CrossRef
  33.Moussaud S, Jones DR, Moussaud-Lamodiere EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener 2014;9:43.PubMedCentral PubMed CrossRef
  34.Jose JC, Chatterjee P, Sengupta N. Cross dimerization of amyloid-beta and alphasynuclein proteins in aqueous environment: a molecular dynamics simulations study. PloS One 2014;9:e106883.PubMedCentral PubMed CrossRef
  35.Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PloS One 2008;3:e3135.PubMedCentral PubMed CrossRef
  36.Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 2006;31:1153-1162.PubMed CrossRef
  37.Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis 2012;2012:391438.PubMedCentral PubMed
  38.Chesser AS, Pritchard SM, Johnson GV. Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol 2013;4:122.PubMedCentral PubMed CrossRef
  39.Takahashi M, Suzuki M, Fukuoka M, et al. Normalization of overexpressed alpha-synuclein causing Parkinson's disease by a moderate gene silencing with RNA interference. Mol Ther Nucleic Acids 2015;4:e241.PubMed CrossRef
  40.Maraganore DM. Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease. J Mov Disord 2011;4:1-7.PubMedCentral PubMed CrossRef
  41.Nielsen TT, Nielsen JE. Antisense gene silencing: therapy for neurodegenerative disorders? Genes 2013;4:457-484.PubMedCentral PubMed CrossRef
  42.Xu H, Rosler TW, Carlsson T, et al. Tau Silencing by siRNA in the P301S Mouse model of Tauopathy. Curr Gene Ther 2014;14:343-351.PubMed CrossRef
  43.Farr SA, Erickson MA, Niehoff ML, Banks WA, Morley JE. Central and peripheral administration of antisense oligonucleotide targeting amyloid-beta protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AbetaPPswe) mice. J Alzheimer Dis 2014;40:1005-1016.
  44.Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008;47:9678-9687.PubMedCentral PubMed CrossRef
  45.Spencer B, Michael S, Shen J, et al. Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD. Mol Ther 2013;21:31-41.PubMedCentral PubMed CrossRef
  46.Devi L, Ohno M. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol Brain 2015;8:19.PubMedCentral PubMed CrossRef
  47.Danzer KM, Ruf WP, Putcha P, et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2011;25:326-336.PubMedCentral PubMed CrossRef
  48.Evans CG, Wisen S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006;281:33182-33191.PubMed CrossRef
  49.Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC. Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry 2012;51:888-898.PubMedCentral PubMed CrossRef
  50.Hashimoto M, Rockenstein E, Mante M, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004;11:1713-1723.PubMed CrossRef
  51.Caruana M, Högen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 2011;585:1113-1120.PubMed CrossRef
  52.Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742-750.PubMed CrossRef
  53.Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett 2015;589:77-83.PubMedCentral PubMed CrossRef
  54.Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther 2013;138:311-322.PubMedCentral PubMed CrossRef
  55.Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 2009;15 (Suppl 3):S143-S147.PubMed CrossRef
  56.Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27:9220-9232.PubMed CrossRef
  57.Jones EM, Dubey M, Camp PJ, et al. Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption. Biochemistry 2012;51:2539-2550.PubMedCentral PubMed CrossRef
  58.Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-6024.PubMed CrossRef
  59.Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 2007;82:1083-1094.PubMed CrossRef
  60.Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010;184:2261-2271.PubMedCentral PubMed CrossRef
  61.Wang A, Das P, Switzer RC, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 2011;31:4124-4136.PubMedCentral PubMed CrossRef
  62.Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.PubMed CrossRef
  63.Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 2013;288:33081-33095.PubMedCentral PubMed CrossRef
  64.Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 2009;8:7-15.PubMed CrossRef
  65.Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 2015;10:10.PubMedCentral PubMed CrossRef
  66.Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014;127:861-879.PubMedCentral PubMed CrossRef
  67.Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012;87:10-20.PubMed CrossRef
  68.Yuste JE, Tarragon E, Campuzano CM, Ros-Bernal F. Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci 2015;9:322.PubMedCentral PubMed CrossRef
  69.Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009;4:47.PubMedCentral PubMed CrossRef
  70.Schott JM, Revesz T. Inflammation in Alzheimer's disease: insights from immunotherapy. Brain 2013;136:2654-2656.PubMed CrossRef
  71.Hutter-Saunders JA, Mosley RL, Gendelman HE. Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother 2011;11:1703-1715.PubMedCentral PubMed CrossRef
  72.Hickman DT, Lopez-Deber MP, Ndao DM, et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 2011;286:13966-13976.PubMedCentral PubMed CrossRef
  73.Muhs A, Hickman DT, Pihlgren M, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 2007;104:9810-9815.PubMedCentral PubMed CrossRef
  74.Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 2013;33:4923-4934.PubMedCentral PubMed CrossRef
  75.Lannfelt L, Moller C, Basun H, et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils—a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer Res Ther 2014;6:16.CrossRef
  76.Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012;32:9677-9689.PubMed CrossRef
  77.Boada M, Ramos-Fernandez E, Guivernau B, et al. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Neurologia 2014;pii:S0213-4853(14)00030-9.
  78.Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimer Dis 2012;28:49-69.
  79.Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207.PubMed CrossRef
  80.Panza F, Solfrizzi V, Imbimbo BP, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Rev Neurother 2014;14:973-986.PubMed CrossRef
  81.Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012;8:261-271.PubMed CrossRef
  82.Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73.PubMed CrossRef
  83.Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012;18 (Suppl. 1):S11-S13.PubMed CrossRef
  84.Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014;34:9441-9454.PubMedCentral PubMed CrossRef
  85.Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimer Res Ther 2014;6:44.CrossRef
  86.Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PloS One 2013;8:e72301.PubMedCentral PubMed CrossRef
  87.Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015;36:693-709.PubMed CrossRef
  88.Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 2014;137:2834-2846.PubMed CrossRef
  89.Wiltfang J, Esselmann H, Bibl M, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.PubMed CrossRef
  90.Maddalena AS, Papassotiropoulos A, Gonzalez-Agosti C, et al. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener Dis 2004;1:231-5.PubMed CrossRef
  91.Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.PubMed CrossRef
  92.Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 1996;93:452-455.PubMedCentral PubMed CrossRef
  93.Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31:9323-9331.PubMed CrossRef
  94.Arai H, Suzuki H, Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr Alzheimer Res 2015;12:242-254.PubMed CrossRef
  95.Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J Nutr Health Aging 2009;13:264-267.PubMed CrossRef
  96.Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-882.PubMedCentral PubMed CrossRef
  97.Hooper DC, Scott GS, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000;14:691-698.PubMed
  98.Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol 2011;31:867-874.PubMedCentral PubMed CrossRef
  99.Lambracht-Washington D, Rosenberg RN. Active DNA Abeta42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci 2012;3:307-313.PubMedCentral PubMed CrossRef
  100.Liu S, Shi D, Wang HC, Yu YZ, Xu Q, Sun ZW. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice. Sci Rep 2015;5:7771.PubMedCentral PubMed CrossRef
  101.Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Abeta42 DNA vaccine for Alzheimer disease. J Neuroimmunol 2013;254:63-68.PubMedCentral PubMed CrossRef
  102.Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.PubMed CrossRef
  103.McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.PubMed CrossRef
  104.Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.PubMed CrossRef
  105.Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA. Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis 2012;10:265-270.PubMedCentral PubMed CrossRef
  106.Zhang Y, He JS, Wang X, et al. Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. J Alzheimer Dis 2011;23:551-561.
  107.Lord A, Gumucio A, Englund H, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2009;36:425-434.PubMed CrossRef
  108.Englund H, Sehlin D, Johansson AS, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007;103:334-345.PubMed
  109.Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing 2013;10:18.PubMedCentral PubMed CrossRef
  110.Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69:1002-1010.PubMed CrossRef
  111.La Porte SL, Bollini SS, Lanz TA, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 2012;421:525-536.PubMed CrossRef
  112.Loeffler DA. Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation 2014;11:198.PubMedCentral PubMed
  113.Spencer B, Masliah E. Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci 2014;6:114.PubMedCentral PubMed CrossRef
  114.Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 2005;25:10913-10921.PubMed CrossRef
  115.George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-372.PubMed CrossRef
  116.Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:11282-11286.PubMedCentral PubMed CrossRef
  117.Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 1996;148:201-210.PubMedCentral PubMed
  118.Tsigelny IF, Bar-On P, Sharikov Y, et al. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 2007;274:1862-1877.PubMed CrossRef
  119.Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46:857-868.PubMed CrossRef
  120.Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PloS One 2011;6:e19338.PubMedCentral PubMed CrossRef
  121.Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;32:13454-13469.PubMedCentral PubMed CrossRef
  122.Tran HT, Chung CH, Iba M, et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 2014;7:2054-2065.PubMedCentral PubMed CrossRef
  123.Shahaduzzaman M, Nash K, Hudson C, et al. Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease. PloS One 2015;10:e0116841.PubMedCentral PubMed CrossRef
  124.Näsström T, Gonçalves S, Sahlin C, et al. Antibodies against alpha-synuclein reduce oligomerization in living cells. PloS One 2011;6:e27230.PubMedCentral PubMed CrossRef
  125.Lindstrom V, Fagerqvist T, Nordstrom E, et al. Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol Dis 2014;69:134-143.PubMed CrossRef
  126.Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986;261:6084-6089.PubMed
  127.Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science 1986;232:648-650.PubMed CrossRef
  128.Lee VM, Otvos L, Schmidt ML, Trojanowski JQ. Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins. Proc Natl Acad Sci U S A 1988;85:7384-7388.PubMedCentral PubMed CrossRef
  129.Iwatsubo T, Hasegawa M, Ihara Y. Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics. Acta Neuropathol 1994;88:129-136.PubMed CrossRef
  130.Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 2004;17:350-354.PubMed CrossRef
  131.Mandelkow EM, Mandelkow E. Tau as a marker for Alzheimer's disease. Trends Biochem Sci 1993;18:480-483.PubMed CrossRef
  132.Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.PubMed CrossRef
  133.Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-88.PubMed CrossRef
  134.Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 2012;165:1246-1259.PubMedCentral PubMed CrossRef
  135.Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 2011;8:659-665.PubMed CrossRef
  136.Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-9129.PubMed CrossRef
  137.Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658-667.PubMedCentral PubMed CrossRef
  138.Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559-16566.PubMedCentral PubMed CrossRef
  139.Wisniewski T, Boutajangout A. Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med 2010;77:17-31.PubMedCentral PubMed CrossRef
  140.Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286:34457-34467.PubMedCentral PubMed CrossRef
  141.Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J Mol Neurosci 2011;45:690-695.PubMedCentral PubMed CrossRef
  142.Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012;9:397-405.PubMedCentral PubMed CrossRef
  143.Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance vs. blocking neuronal uptake. J Biol Chem 2015;290:21652-21662.PubMed CrossRef
  144.Umeda T, Eguchi H, Kunori Y, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2015;2:241-255.PubMedCentral PubMed CrossRef
  145.Sankaranarayanan S, Barten DM, Vana L, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PloS One 2015;10:e0125614.PubMedCentral PubMed CrossRef
  146.d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PloS One 2013;8:e62402.PubMedCentral PubMed CrossRef
  147.Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014;34:4260-4272.PubMed CrossRef
  148.Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J Neurosci 2015;35:4857-4868.PubMed CrossRef
  149.Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.PubMed CrossRef
  150.Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 2013;288:35452-35465.PubMedCentral PubMed CrossRef
  151.Spencer B, Emadi S, Desplats P, et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 2014;22:1753-1767.PubMedCentral PubMed CrossRef
  152.Emadi S, Liu R, Yuan B, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004;43:2871-2878.PubMed CrossRef
  153.Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007;368:1132-1144.PubMedCentral PubMed CrossRef
  154.Bousset L, Pieri L, Ruiz-Arlandis G, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013;4:2575.PubMedCentral PubMed CrossRef
  155.Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR. Bispecific tandem single chain antibody simultaneously inhibits beta-secretase and promotes alpha-secretase processing of AbetaPP. J Alzheimer Dis 2012;28:961-969.
  156.Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004;10:1023-1031.PubMed CrossRef
  157.Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 2008;377:136-147.PubMedCentral PubMed CrossRef
  158.Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs 2012;4:686-693.PubMedCentral PubMed CrossRef
  159.Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 2011;31:7604-7618.PubMedCentral PubMed CrossRef
  160.Badiola N, de Oliveira RM, Herrera F, et al. Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PloS One 2011;6:e26609.PubMedCentral PubMed CrossRef
  161.Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389-397.PubMed CrossRef
  162.Iwai A. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 2000;1502:95-109.PubMed CrossRef
  163.Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999;843:53-61.PubMed CrossRef
  164.Willet M, Kurup D, Papaneri A, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis 2015;212(Suppl. 2):S414-S424.PubMed CrossRef
  165.Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res 2005;123:157-180.PubMed CrossRef
  166.Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PloS One 2011;6:e18513.PubMedCentral PubMed CrossRef
  167.Maetzler W, Berg D, Synofzik M, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimer Dis 2011;26:171-179.
  168.Wilhelm KR, Yanamandra K, Gruden MA, et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol 2007;14:327-334.PubMed
  169.O'Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006;176:7071-7078.PubMed CrossRef
  170.Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ. Cerebrospinal fluid beta-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease—systematic review and meta-analysis. PloS One 2015;10:e0116802.PubMedCentral PubMed CrossRef
  171.Krishnaswamy S, Lin Y, Rajamohamedsait WJ, Rajamohamedsait HB, Krishnamurthy P, Sigurdsson EM. Antibody-derived in vivo imaging of tau pathology. J Neurosci 2014;34:16835-16850.PubMedCentral PubMed CrossRef
  172.Frisoni GB, Visser PJ. Biomarkers for Alzheimer's disease: a controversial topic. Lancet Neurol 2015;14:781-783.PubMed CrossRef
  173.Rakover I, Arbel M, Solomon B. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 2007;4:392-402.PubMed CrossRef
  174.Gros-Louis F, Soucy G, Larivière R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010;113:1188-1199.PubMed
  175.Takeuchi S, Fujiwara N, Ido A, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010;69:1044-1056.PubMed CrossRef
  176.Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007;104:2495-2500.PubMedCentral PubMed CrossRef
  
• 作者单位：Elvira Valera (1)
  Brian Spencer (1)
  Eliezer Masliah (1) (2)
  
  1. Department of Neurosciences, University of California, La Jolla, San Diego, CA, 92093, USA
  2. Department of Pathology, University of California, La Jolla, San Diego, CA, 92093, USA
  
• 刊物主题：Neurosciences; Neurology; Neurosurgery; Neurobiology;
• 出版者：Springer US
• ISSN：1878-7479

文摘

Disease-modifying alternatives are sorely needed for the treatment of neurodegenerative disorders, a group of diseases that afflict approximately 50 million Americans annually. Immunotherapy is one of the most developed approaches in this direction. Vaccination against amyloid-β, α-synuclein, or tau has been extensively explored, specially as the discovery that these proteins may propagate cell-to-cell and be accessible to antibodies when embedded into the plasma membrane or in the extracellular space. Likewise, the use of passive immunization approaches with specific antibodies against abnormal conformations of these proteins has also yielded promising results. The clinical development of immunotherapies for Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies, and other neurodegenerative disorders is a field in constant evolution. Results to date suggest that immunotherapy is a promising therapeutic approach for neurodegenerative diseases that progress with the accumulation and prion-like propagation of toxic protein aggregates. Here we provide an overview of the most novel and relevant immunotherapeutic advances targeting amyloid-β in Alzheimer’s disease, α-synuclein in Alzheimer’s disease and Parkinson’s disease, and tau in Alzheimer’s disease and frontotemporal dementia. Key Words Immunotherapy Vaccines Antibodies Amyloid-β α-synuclein Tau